The company will focus on the development of
novel DNA-damage repair (DDR) inhibitors for the treatment of
cancer
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED
STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY
CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW./
VANCOUVER, BC, April 1, 2021 /CNW/ - Rakovina Therapeutics
Inc. (the "Company") (TSX-V: RKV) is pleased to
announce the commencement of trading on the TSX Venture Exchange
under the symbol "RKV" following the completion of its previously
announced qualifying transaction (the "Qualifying
Transaction"), the detail of which is described in the
Company's press release dated March 25,
2021 and prior announcements available at www.sedar.com.
In connection with the closing of the qualifying transaction and
commencement of trading the Company:
- Acquired certain rights to three novel series of DNA-damage
response inhibitors
- Raised gross proceeds of $4,565,900 in an oversubscribed private
placement
- Established a research collaboration with the University of British Columbia to undertake
lead-optimization and pre-clinical development activities
- Appointed Jeffrey Bacha
(Executive Chairman), Mads Daugaard
(President & CSO), John
Langlands (COO) and David
Hyman (CFO & Corporate Secretary) as Executive
Officers
- Appointed Jeffrey Bacha,
Dennis Brown, Al Delucrezia and Michael Liggett to the Board of Directors
"The capitalization of Rakovina Therapeutics and commencement of
trading on the TSX Venture Exchange is a major milestone in
our commitment to extending the lives and improving outcomes of
patients with cancer," said Mr. Jeffrey
Bacha, Rakovina Therapeutics' executive chairman. "We
are pleased to assemble this experienced team to lead research
conducted through our collaboration with the University of British Columbia with the near-term
goal of building upon already-established proof-of-concept data and
advancing Rakovina's drug candidates toward human clinical trials,"
concluded Mr. Bacha.
Rakovina Therapeutics will begin trading as a Tier 2 Issuer on
the TSX Venture Exchange ("TSXV") under the symbol
"RKV".
About Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc. was established in 2020 to develop
new cancer treatments based on novel DNA-damage response
technologies. The Company has established a pipeline of
DNA-damage response inhibitors with the goal of advancing one or
more drug candidates into human clinical trials and obtaining
marketing approval for new cancer therapeutics from Health Canada,
the United States Food and Drug Administration and similar
international regulatory agencies. Further information may be
found at www.rakovinatherapeutics.com.
Additional Information
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities in any
jurisdiction.
The TSXV has in no way passed upon the merits of the
Qualifying Transaction and has neither approved nor disapproved the
content of this press release. Neither the TSXV nor its Regulation
Services Provider (as that term is defined in policies of the TSXV)
accepts responsibility for the adequacy or accuracy of this
release.
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding
the Company and its respective business, which may include, but is
not limited to, statements with respect to the proposed business
plan of the Company and other statements. Often, but not always,
forward-looking statements can be identified by the use of words
such as "plans", "is expected", "expects", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes" or variations
(including negative variations) of such words and phrases, or state
that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved. Such statements
are based on the current expectations of the management of the
Company. The forward-looking events and circumstances discussed in
this release may not occur by certain specified dates or at all and
could differ materially as a result of known and unknown risk
factors and uncertainties affecting the Company, including risks
regarding the medical device industry, economic factors, regulatory
factors, the equity markets generally and risks associated with
growth and competition. Although the Company has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement
can be guaranteed. Except as required by applicable securities
laws, forward-looking statements speak only as of the date on which
they are made and the Company undertakes no obligation to publicly
update or revise any forward-looking statement, whether as a result
of new information, future events, or otherwise. The
reader is referred to the Company's most recent filings on SEDAR
for a more complete discussion of all applicable risk factors and
their potential effects, copies of which may be accessed through
the Company's profile page at www.sedar.com.
SOURCE Rakovina Therapeutics Inc.